

## Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
06/30/2021	45,461,310	51,531,339

### About Collectis

Collectis is a gene editing company, developing first of its kind therapeutic products. Collectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Collectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.

As part of its commitment to a cure, Collectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Collectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit [www.collectis.com](http://www.collectis.com)

Follow Collectis on social media: @collectis, LinkedIn and YouTube.

### For further information, please contact:

#### Media contacts:

Pascalyné Wilson, Director, Communications, +33776991433, [media@collectis.com](mailto:media@collectis.com)

#### IR contact:

Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, [investors@collectis.com](mailto:investors@collectis.com)

###